What question did this study set out to answer?

This investigation assesses how first- and second-line treatment choices affect progression-free and overall survival in HR+ HER2- metastatic breast cancer.

February 22, 2026Clinical Cancer Research

Abstract PS2-04-11: Treatment Sequencing in HR+ HER2- Metastatic Breast Cancer and Associated Real World Outcomes

View Full Paper

Ask AI

Bookmark

Authors

NMN. P. McAndrewSarcoma Oncology Center ECE. T. CorcoranTempus Labs (United States)SAS. AlkassisSarcoma Oncology Center

Discussion

Member takes

Implication

Demonstrates treatment sequencing influences survival outcomes in patients with HR+ HER2- metastatic breast cancer, suggesting modification of treatment strategies could enhance efficacy.

Key Points

This investigation assesses how first- and second-line treatment choices affect progression-free and overall survival in HR+ HER2- metastatic breast cancer.
Analyzed 13,064 patients from a real-world multimodal database.
Utilized Kaplan-Meier survival analysis for rwPFS and rwOS assessment.
Applied multivariate Cox regression to adjust for confounding variables.
Examined DNA sequencing data for mutation landscapes related to treatment sequencing.
Patients on 1L CDK4/6i + endocrine therapy had significantly improved rwPFS and rwOS than those on taxanes.
Observed trend of accelerated progression with taxane as a 2L treatment after 1L CDK4/6i (HR=1.33, P=0.052).
Re-challenging patients with CDK4/6i after 1L showed the longest 2L rwPFS.
2L rwPFS was longer for patients receiving CDK4/6i versus non-CDK4/6i post 1L taxane (median 5.9 months vs 3.6 months).
2L response favored CDK4/6i after 1L taxane, indicating potential sensitization.

Cite This Study

McAndrew et al. (2026) studied this question.

synapsesocial.com/papers/699a9d8e482488d673cd38af https://doi.org/10.1158/1557-3265.sabcs25-ps2-04-11

View Full Paper

Ask AI

Bookmark

Implication

Demonstrates treatment sequencing influences survival outcomes in patients with HR+ HER2- metastatic breast cancer, suggesting modification of treatment strategies could enhance efficacy.

Abstract PS2-04-11: Treatment Sequencing in HR+ HER2- Metastatic Breast Cancer and Associated Real World Outcomes

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS2-04-11: Treatment Sequencing in HR+ HER2- Metastatic Breast Cancer and Associated Real World Outcomes

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider